Investor Presentation Delivering therapy where it matters® March 2025 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT Cautionary Note Regarding Forward-Looking Statements This presentation and statements of the Company's management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) the potential of RenovoCath® or TAMP ...

Core Insights - Allarity Therapeutics has developed a new Drug Response Predictor (DRP) for the monoclonal antibody daratumumab, aimed at identifying multiple myeloma patients who are most likely to benefit from the treatment [1][2][3] Group 1: Drug Response Predictor Development - The daratumumab DRP was created by analyzing gene expression patterns related to sensitivity and resistance to daratumumab-induced antibody-dependent cellular cytotoxicity (ADCC), identifying 53 genes in total [2] - The DRP utilizes single-cell RNA sequencing data and clinical response information from the KYDAR trial, demonstrating its ability to predict treatment outcomes and survival in multiple myeloma patients [2] Group 2: Company Strategy and Technology - The introduction of the daratumumab DRP marks the first application of Allarity's DRP technology for an antibody therapy, expanding its portfolio beyond small-molecule drugs [3] - The company aims to position itself as a strategic partner for third parties looking to target the right patients with existing cancer therapies, enhancing its potential for future collaborations [3] Group 3: Clinical and Regulatory Context - Daratumumab is already approved by the FDA and EMA for treating multiple myeloma, marketed under the brand name Darzalex [5] - Allarity has developed DRPs for numerous anticancer drugs, including its lead program, stenoparib, which is in Phase 2 development for advanced ovarian cancer [6][11]

Core Viewpoint - Intensity Therapeutics, Inc. has announced a public offering of 3,133,333 shares of common stock and accompanying warrants, aiming to raise approximately $2.35 million to fund clinical studies and general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes Series B-1 and Series B-2 common warrants, both with an exercise price of $0.85 per share [2]. - The Series B-1 warrants will expire 5 years from issuance, while the Series B-2 warrants will expire 18 months from issuance [2]. - The offering is expected to close on or about April 28, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for patient enrollment in the INVINCIBLE-4 Study, treatment of patients in the INVINCIBLE-3 Study, and for working capital and general corporate purposes [3]. Group 3: Company Overview - Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing immune-based intratumoral cancer therapies [7]. - The company has completed two clinical studies and enrolled over 200 patients using its lead product, INT230-6, which has shown potential in treating various cancers [7]. - Ongoing studies include a Phase 3 trial in soft tissue sarcoma and a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research [7].

Core Insights - Helix BioPharma Corp. has appointed Veronika Kandziora as Chief Operating Officer and Dr. Jessica Kourniaktis as Director of Communications, aiming to strengthen its leadership team during a pivotal stage of development [1][4][5] Leadership Appointments - Veronika Kandziora brings over 20 years of experience in biopharma, financial, and consulting sectors, with a strong background in corporate strategy and stakeholder engagement [2] - Dr. Jessica Kourniaktis has 10 years of experience in life sciences communications, having founded a consultancy and served in leadership roles in biopharma startups [3] Company Vision and Strategy - The company is focused on developing novel therapies for hard-to-treat cancers, with a diverse pipeline of drug candidates [6] - The lead candidate, Tumour Defence Breaker™ L-DOS47, is designed to neutralize the microenvironment of solid tumors and has completed Phase Ib studies in non-small cell lung cancer [6] Operational Goals - Kandziora emphasizes the need for structure, clarity, and strategic alignment to empower the team and innovate effectively [4] - Kourniaktis aims to enhance the company's communication strategy to better articulate its vision and engage stakeholders [5]

Company Overview - HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [12]. Recent Developments - HUTCHMED announced new and updated data from studies of its compounds, including savolitinib, fruquintinib, and surufatinib, which will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2025 [1]. - The company is actively involved in multiple clinical trials, including the SACHI and SAFFRON trials, assessing the combination of savolitinib with TAGRISSO® (osimertinib) for treating patients with advanced non-small cell lung cancer (NSCLC) [10][11]. Product Information - Savolitinib is a selective MET tyrosine kinase inhibitor developed by HUTCHMED and AstraZeneca, approved in China for treating adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alterations [7][6]. - Fruquintinib is being studied in various treatment regimens for metastatic colorectal cancer (mCRC), with ongoing trials evaluating its efficacy in combination with other therapies [2][3]. Market Context - Lung cancer is the leading cause of cancer death globally, with NSCLC accounting for approximately 80% of cases. A significant portion of NSCLC patients in Asia have epidermal growth factor receptor (EGFR) mutations, which are targetable by therapies like savolitinib [4][5]. - The prevalence of MET aberrations in NSCLC patients who progress after EGFR TKI treatment is notable, with studies indicating that 15-50% of these patients may present with such mutations [8][9]. Clinical Trial Highlights - The SACHI trial met its primary endpoint of progression-free survival (PFS) during its interim analysis, leading to the acceptance of a New Drug Application (NDA) in China [10]. - The SAFFRON trial is ongoing, assessing the combination of savolitinib and TAGRISSO® against platinum-based chemotherapy in a specific patient population [11]. Future Prospects - HUTCHMED is focused on expanding the clinical development of its compounds, with promising data from ongoing trials expected to support potential regulatory filings in the US and other global markets [9][11].

Core Insights - Jazz Pharmaceuticals is presenting significant clinical trial data at the ASCO Annual Meeting, highlighting the potential of Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) for first-line maintenance therapy in extensive-stage small cell lung cancer (ES-SCLC) [1][2] - The company is also showcasing long-term outcomes for Ziihera® (zanidatamab-hrii) in HER2-positive gastroesophageal cancer, indicating its potential to change treatment paradigms [1][2] - Efficacy and safety data for dordaviprone (ONC201) in recurrent H3 K27M-mutant diffuse glioma patients are also being presented, addressing a significant unmet medical need [1][2] Group 1: Zepzelca® (lurbinectedin) - The Phase 3 IMforte trial data shows statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) for Zepzelca in combination with atezolizumab for ES-SCLC patients [2][4] - The FDA has received a supplemental New Drug Application based on this trial data, marking a milestone for Zepzelca's approval process [2][4] - An investor webcast is scheduled for June 10 to review Zepzelca data, featuring commentary from experts [3] Group 2: Ziihera® (zanidatamab-hrii) - Updated long-term outcomes and median overall survival findings from the Phase 2 trial of Ziihera in combination with chemotherapy for HER2-positive metastatic gastroesophageal adenocarcinoma will be presented [2][4] - Ziihera is positioned as a differentiated HER2-targeted therapy, with further Phase 3 findings expected later this year [2][4] Group 3: Dordaviprone (ONC201) - New efficacy and safety findings for dordaviprone in adult and pediatric patients with recurrent H3 K27M-mutant diffuse glioma are being highlighted [2][4] - The drug addresses a significant unmet need, as there are currently no FDA-approved therapies for this patient population [2][4] Group 4: Company Overview - Jazz Pharmaceuticals is committed to advancing targeted treatment options that address pressing patient needs, with a focus on oncology and neuroscience [55] - The company has a diverse portfolio of marketed medicines and is dedicated to developing potentially life-changing therapies for serious diseases [55]

Core Insights - Nuvalent, Inc. is presenting two "Trial in Progress" posters for its novel ALK-selective inhibitor neladalkib and HER2-selective inhibitor NVL-330 at the 2025 ASCO Annual Meeting [1][2][3] Group 1: Neladalkib - Neladalkib is being evaluated in the ALKAZAR Phase 3 trial, which is a global, randomized, controlled study comparing neladalkib to ALECENSA® for TKI-naïve ALK-positive non-small cell lung cancer (NSCLC) [2][4] - The ALKAZAR trial is set to initiate in the first half of 2025, with a 1:1 randomization for patients to receive either neladalkib monotherapy or ALECENSA® monotherapy [2] - Neladalkib is designed to penetrate the brain and remain effective against tumors that have developed resistance to existing ALK inhibitors, including those with specific mutations [4][6] Group 2: NVL-330 - NVL-330 is currently being assessed in the HEROEX-1 Phase 1a/1b clinical trial, focusing on safety and tolerability for pre-treated patients with HER2-altered NSCLC [3][5] - The trial aims to determine the recommended Phase 2 dose and evaluate the pharmacokinetic profile and preliminary anti-tumor activity of NVL-330 [3] - NVL-330 is designed to treat HER2-mutant tumors while minimizing adverse events related to off-target inhibition of wild-type EGFR and addressing brain metastases [5][6] Group 3: Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, aiming to overcome limitations of existing treatments [6] - The company is advancing a robust pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered NSCLC, along with multiple discovery-stage research programs [6]

Core Insights - Adagene Inc. is set to present a poster at ASCO 2025, showcasing its advancements in antibody-based therapies [1][2] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [3] - The company has established strategic collaborations with global partners to enhance its SAFEbody precision masking technology [3] Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, aimed at addressing safety and tolerability issues in antibody therapeutics [4] - The SAFEbody technology allows for tumor-specific targeting of antibodies while minimizing toxicity to healthy tissues [4] Clinical Programs - The lead clinical program, ADG126 (muzastotug), is an anti-CTLA-4 SAFEbody currently in phase 1b/2 studies, focusing on Metastatic Microsatellite-stable Colorectal Cancer [5] - ADG126 targets a unique epitope of CTLA-4 in regulatory T cells within the tumor microenvironment and is being studied in combination with anti-PD-1 therapy [5] Upcoming Presentation Details - The poster presentation titled "Safety and Efficacy of ADG126 (an Anti-CTLA-4 Masking Antibody) in Combination with Pembrolizumab" will take place on May 31, 2025, at ASCO 2025 [7]

Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session Independent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating 95% of patients said they would choose thermal ablation over breast conserving surgery In-booth expert exchange session on breast cancer cryoablation from the perspective of both breast surgeons and interventional oncologists by Sophie Wooldrik, MD & Prof. Tomas Vogl, MD respectively Three h ...

Core Insights - Moleculin Biotech, Inc. announced that an abstract regarding its next-generation anthracycline, Annamycin, has been selected for poster presentation at the AACR Annual Meeting 2025 [1][2] Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat cancers and viruses [3] - The lead program, Annamycin, is designed to avoid multidrug resistance and eliminate cardiotoxicity associated with current anthracyclines, targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3] Clinical Trials - The company is initiating the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML [4] - Following a successful Phase 1B/2 study, the company believes it has de-risked the development pathway towards potential approval for Annamycin [4] Additional Developments - Moleculin is also developing WP1066, an immune/transcription modulator targeting brain tumors and other cancers, and a portfolio of antimetabolites including WP1122 for treating pathogenic viruses and certain cancer indications [5]